

Andreas Ziegler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1232397/publications.pdf>

Version: 2024-02-01

18
papers

710
citations

759233

12
h-index

677142

22
g-index

23
all docs

23
docs citations

23
times ranked

943
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 17-27.	5.6	57
2	Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy. <i>European Journal of Neurology</i> , 2022, 29, 2084-2096.	3.3	13
3	Response to letter: A decision for life – Treatment decisions in newly diagnosed families with spinal muscular atrophy. <i>European Journal of Paediatric Neurology</i> , 2021, 30, 103-104.	1.6	1
4	Biallelic and monoallelic variants in <i>PLXNA1</i> are implicated in a novel neurodevelopmental disorder with variable cerebral and eye anomalies. <i>Genetics in Medicine</i> , 2021, 23, 1715-1725.	2.4	22
5	Bi-allelic variants in <i>SPATA5L1</i> lead to intellectual disability, spastic-dystonic cerebral palsy, epilepsy, and hearing loss. <i>American Journal of Human Genetics</i> , 2021, 108, 2006-2016.	6.2	11
6	¹ H-NMR-based metabolic profiling identifies non-invasive diagnostic and predictive urinary fingerprints in 5q spinal muscular atrophy. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 441.	2.7	8
7	Mitochondrial Transporter Defects: Successful Treatment with Ketogenic Diet Therapy. <i>Neuropediatrics</i> , 2021, 52, .	0.6	0
8	Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy. <i>Journal of Neurochemistry</i> , 2020, 153, 650-661.	3.9	44
9	Defining the clinical, molecular and imaging spectrum of adaptor protein complex 4-associated hereditary spastic paraplegia. <i>Brain</i> , 2020, 143, 2929-2944.	7.6	29
10	Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 317-325.	10.2	196
11	European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. <i>European Journal of Paediatric Neurology</i> , 2020, 28, 38-43.	1.6	74
12	Axenfeld-Rieger Anomaly and Neuropsychiatric Problems – More than Meets the Eye. <i>Neuropediatrics</i> , 2020, 51, 192-197.	0.6	5
13	CASPR2 autoimmunity in children expanding to mild encephalopathy with hypertension. <i>Neurology</i> , 2020, 94, e2290-e2301.	1.1	26
14	Pathogenic <i>WDFY3</i> variants cause neurodevelopmental disorders and opposing effects on brain size. <i>Brain</i> , 2019, 142, 2617-2630.	7.6	31
15	Quantitative MR neurography biomarkers in 5q-linked spinal muscular atrophy. <i>Neurology</i> , 2019, 93, e653-e664.	1.1	24
16	Novel challenges in spinal muscular atrophy – How to screen and whom to treat?. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 197-205.	3.7	30
17	Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2% years of age – a multicenter retrospective study. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 96.	2.7	90
18	Serological and biochemical characterization of HLA-A molecules bearing a public epitope. <i>Immunogenetics</i> , 1988, 27, 61-65.	2.4	5